online here. Drug class: Miscellaneous antivirals. 1998-2023 Mayo Foundation for Medical Education and Research (MFMER). In a statement the FDA said that it was "carefully monitoring circulating viral variants and their sensitivity to authorised monoclonal antibodies . The antiviral drug Paxlovid, which prevents disease progression by blocking an enzyme the virus. It is used by people 12 years of age and older who have recently tested positive for. Infusion-related reactions, which may occur up to 24 hours after the injection, have been observed in clinical trials of bebtelovimab when administered with other . Mayo Clinic does not endorse companies or products. Healthcare professionals must follow aseptic technique directive provided by their institution for preparation ofthebebtelovimabinjection.3, Bebtelovimabcontains no preservative. We have been isolating and using N95s when we use the bathroom, opening windows & leaving a good 12 hours between us each showering etc. 1 Preparation and Administration Contact your healthcare provider if you have any side effects that bother you or do not go away. Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk patients with. Limitations of Benefit and Potential Risk in Patients with Severe COVID-19. One dose given per day for 3 days. Monoclonal antibodies, such as bebtelovimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation. Serious and unexpected adverse events may occur that have not been previously reported with bebtelovimab use. Tell your doctor right away if you start to have a fever, chill or shaking, dizziness, headache, hoarseness, increased sweating, trouble breathing, trouble swallowing, itching or skin rash, lightheadedness, fainting, fast, pounding, or uneven heartbeat, or any swelling of your hands, face, or mouth after receiving this medicine. more serious infusion related hypersensitivity reactions. Descriptions Bebtelovimab injection is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in patients with positive results of direct SARS-CoV-2 testing, who are at high risk for progression to severe COVID-19 (eg, hospitalization, death), and for whom other treatments are not available or appropriate. Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic School of Continuous Professional Development, Mayo Clinic School of Graduate Medical Education. All rights reserved. The procedure followed for aseptic technique may vary between institutions. Per EUA, remove bebtelovimab vial from refrigerator and allow to equilibrate to room temperature for approximately 20 minutes. 0.9% Sodium Chloride injection for flushing. are likely to be infected with a SARS-CoV-2 variant that is not able to be treated by bebtelovimab based on the circulating variants in your area (ask your health care provider about FDA and CDCs latest information on circulating variants by geographic area). Use the filters to find locations for vaccines, testing and treatments for COVID-19 near you. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Monoclonal antibody drugs are designed to start working faster than vaccines, while protection provided by vaccines may last longer. (1-800-545-5979), HCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter. MedWatch adverse event reports can be submitted to the FDA by calling 1-800-FDA-1088 or https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvYmVidGVsb3ZpbWFiLTQwMDAyNzM=. To ensure there is no break in availability of bebtelovimab to states/territories and providers, HHS has coordinated with Lilly to enable the transition from US government distributed supply to commercially available supply. Current variant frequency data are available here. Discard the vial if the solution is cloudy, discolored, or visible particles are observed. It is very important that your doctor check you or your child's progress closely while you are receiving this medicine to make sure that it is working properly. . 1 Bebtelovimab vial (175 mg/2 mL) 1 disposable polypropylene dosing syringe capable of holding 2 mL 0.9% Sodium Chloride Injection for flushing Optional: 1 syringe extension set made of polyethylene or polyvinylchloride with or without di-ethylhexylphthalate (DEHP) Preparation Add Resources to Your . Severe hypersensitivity reactions and infusion-related reactions, have been observed with administration of bebtelovimab, including in pregnant patients.
This medicine may cause serious allergic reactions, including infusion-related reactions and anaphylaxis, which can be life-threatening and require immediate medical attention. Other risk factors can be found on the CDC website. All rights reserved. If immediate administration is not possible, store the syringe for up to 24 hours at refrigerated temperature (2C to 8C [36F to 46F]) and up to 7 hours at room temperature (20C to 25C [68F to 77F]). Your healthcare provider may talk with you about clinical trials for which you may be eligible. The drug, bebtelovimab, is authorized for people 12 years and older who test positive for COVID-19 and are at high risk of hospitalization or death. Tell your doctor right away if you feel confused, tired, or weak. Bebtelovimab has been associated with anaphylactic reactions; however, this is unlikely in our . These therapies require a prescription by a licensed and authorized provider. Lagevrio is authorized for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.
Tell your doctor if you are pregnant or plan to become pregnant before using bebtelovimab; severe hypersensitivity reactions and infusion-related reactions, have been observed with administration of bebtelovimab, including in pregnant patients. This site is intended for US Healthcare Professionals only. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. The emergency use of bebtelovimab is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. Available for Android and iOS devices. Bebtelovimab is clear to opalescent and colorless to slightly yellow to slightly brown solution. Like bebtelovimab, FDA may allow for the emergency use of other medicines to treat people with COVID-19. Important points to this press release: "Severe hypersensitivity reactions and infusion-related reactions, have been observed with administration of bebtelovimab, including in pregnant patients. There areseveral treatmentsthat are authorized or approved to treat certain patients with mild-to-moderate COVID-19 which are expected to retain activity against currently circulating variants, including Omicron subvariants BQ.1 and BQ.1.1. Information about circulating variants can be found through Nowcast data. Bebtelovimab is authorized to be administered for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg): The following provides essential safety information on the unapproved use of bebtelovimab under the Emergency Use Authorization. To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. If you have any questions regarding the procurement of bebtelovimab commercially, please contact Call the infusion center to confirm product availability. Lilly cannot recommend other methods of administration other than what is authorized in the EUA Fact Sheet for health care providers. Accessed February 11, 2022. http://pi.lilly.com/eua/bebtelovimab-eua-fda-authorization-letter.pdf. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. with positive results of direct SARS-CoV-2 viral testing. Across the company's safety studies, the drug was found to cause rare instances of relatively mild side effects, including infusion-related reactions, itchiness and a rash. How do I find COVID-19 antibody therapies? Current variant frequency data are available here. These reactions may be severe or life-threatening. Individuals 12 and older who are considered high risk of getting very sick from COVID-19, with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom other COVID-19 treatment options approved or authorized by FDA are not available or clinically appropriate and may qualify for a monoclonal antibody treatment. Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other mAbs that have been authorized for the treatment of high-risk patients with mild to moderate COVID-19 and shown a benefit in reducing the risk for hospitalization or death. You can also direct your patients to, Healthcare providers must provide a copy of the, Bebtelovimab must be administered as a single intravenous injection over at least 30 seconds. Before sharing sensitive information, make sure you're on a federal government site. were randomized 1:1:1 to receive a single infusion of a combination of 3 anti-SARS-CoV-2 mAbs (bamlanivimab, etesevimab, and bebtelovimab; n = 127), bebtelovimab alone (n = 125), or placebo (n = 128). The new infusion provides an . I was given the Bebtelovimab infusion and I did well with it. Veklury is approved for the treatment of adults and pediatric patients (28 days of age and older and weighing at least 3 kg) with positive results of direct SARS-CoV-2 viral testing, who are: hospitalized, or not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. ).1, In the BLAZE 4 study, extension sets could have been primed with either study drug or normal saline if allowed by site practices.3, Bebtelovimab Fact Sheet for Health Care Providers. Bebtelovimab . Please see the enclosed Fact Sheet for authorized dosing information. There is limited experience treating pregnant women or breastfeeding mothers with bebtelovimab. . Bebtelovimab is authorized for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and. All rights reserved. Health care providers should assess whether these treatments are right for their patient in the event the patient develops mild-to-moderate COVID-19. Medically reviewed by Melisa Puckey, BPharm. Healthcare providers should consider the benefit-risk for an individual patient. One day after the United States announced a supply deal for Eli Lilly's new COVID-19 monoclonal antibody treatment, bebtelovimab, the FDA How do you prepare, administer, and monitor bebtelovimab for treatment of COVID-19? Lilly USA, LLC is not responsible for the privacy policy of any third-party websites.
If you log out, you will be required to enter your username and password the next time you visit. Fact Sheet for Healthcare Providers, Download Vaccines provide active immunity by helping the body make its own antibodies to protect itself. fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g. The Florida Department of Health COVID-19 Response Map has been updated to make it easier to find testing, vaccine and treatment sites across the state. A prescription from a healthcare provider is required to receive any mAb therapy. Serious and unexpected side effects may happen. This information shows that bebtelovimab is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. Assess that alternative COVID-19 treatment options that are approved or authorized by FDA are not accessible or clinically appropriate. Positive results of direct acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing. Thebebtelovimabinjectionshould be prepared by a qualified healthcare professional using aseptic technique to prevent contamination from pathogens.3, Bebtelovimabis neither hazardous nor toxic when spilled.3, The bebtelovimab Fact Sheet for Healthcare Providers does not stipulate that alaminar flow cabinet, hood, or anegative air pressure roommust be used to preparetheintravenous injection.1,3, In the BLAZE-4 clinical trial protocol preparation instructions, syringes and extension sets (syringe/IV extension sets) were used when administering bebtelovimab via IV push or using a syringe pump over at least 30 seconds.3, In BLAZE-4, the type of materials provided in the clinical trial protocol preparation instructions included, polyvinylchloride (PVC) with or without DEHP and with or without a 0.20/0.22 m polyether sulfone (PES) filter, polyethylene with or without a 0.20/0.22 m PES filter.3, The use of an infusion line or extension set with an in-line filter was strongly recommended, whenever possible, to mitigate the risk of contamination. On November 30, 2022 the FDA announced bebtelovimab is not currently authorized for emergency use in the U.S. at this time because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions. 1,2, BLAZE-4 is a phase 2, randomized, single-dose clinical trial evaluating treatment of non-hospitalized patients with mild-to-moderate COVID-19.1, Bebtelovimab was among the treatment interventions studied in BLAZE-4. The Food and Drug Administration (FDA) issued an emergency use authorization for bebtelovimab on Feb. 11. Bebtelovimab, pronounced: beb-te-LOV-i-mab. Monoclonal antibodies, such as bebtelovimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. If refrigerated, allow the prepared syringe to equilibrate to room temperature for approximately 20. Veklury is approved for the treatment of adults and pediatric patients (28 days of age and older and weighing at least 3 kg) with positive results of direct SARS-CoV-2 viral testing, who are:. Fact Sheet for Patients, Parents and Caregivers (Spanish), Download Generic name: bebtelovimab These errors build up over time until the virus is no longer capable of surviving. It is your choice for you or your child to be treated or not to be treated with bebtelovimab. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. This content does not have an English version. Not many people have received bebtelovimab. We encourage you to read the privacy policy of every website you visit.Click "Continue" to proceed or "Return" to return to LillyMedical.com. The U.S. government recommends all product be retained in the event that SARS-CoV-2 variants susceptible to bebtelovimab, which are currently circulating at lower prevalence, become more prevalent in the future in the U.S. Are taking any medicines (prescription, and over-the-counter, vitamins, or herbal products). Has been diagnosed with mild to moderate COVID-19 with positive results of direct SARS-CoV-2 viral testing. It looks like your browser does not have JavaScript enabled. The EUA has since been revoked on November 30, 2022. Bebtelovimab is a monoclonal antibody treatment that had its FDA authorization paused in November 2022. High risk for progression to severe COVID-19, including hospitalization or death, Other COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate, Any severity or dialysis: No dosage adjustment recommended, Not expected to impact bebtelovimab pharmacokinetics, since monoclonal antibodies (mAbs) with molecular weight >69 kDa are known not to undergo renal elimination, For use in geographic regions where infection is likely to have been caused by a nonsusceptible SARS-CoV-2 variant based on available information including variant susceptibility, For patients who require oxygen therapy and/or respiratory support due to COVID-19, For patients who require increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support owing to underlying non-COVID-19related comorbidity, Obesity/overweight (body mass index [BMI] 25 kg/m2 [adults]; BMI 85th percentile for age/sex based on CDC growth charts [if aged 12-17 years]), Immunosuppressive disease or immunosuppressive treatment, Cardiovascular disease (including congenital heart disease) or hypertension, Chronic lung diseases (eg, chronic obstructive pulmonary disease [COPD], moderate-to-severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension), Neurodevelopmental disorders (eg, cerebral palsy) or other conditions that confer medical complexity (eg, genetic or metabolic syndromes, severe congenital anomalies), Having a medical-related technological dependence (eg, tracheostomy, gastrostomy, positive-pressure ventilation [not related to COVID 19]), EUA is not limited to the medical conditions or factors listed above; for additional information on medical conditions and factors associated with increased risk for progression to severe COVID, see the, 12 years (weight 40 kg): 175 mg as a single IV injection over at least 30 seconds, Serious hypersensitivity reaction, including anaphylaxis, observed with other COVID-19 mAbs, and may occur with bebtelovimab, Hypersensitivity reactions occurring >24 hr after infusion observed with bebtelovimab when administered with other mAbs, Infusion-related reactions may be severe or life-threatening, If signs and symptoms occur, immediately discontinue IV infusion, and initiate appropriate medications and/or supportive care, Infusion-related reactions reported, including fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vasovagal reactions, dizziness, and diaphoresis, Administer appropriate medication/supportive care if infusion-related reactions occurs, Clinical worsening of COVID-19 after administration reported; signs or symptoms may include fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), fatigue, and altered mental status, Some of these events required hospitalization, Unknown if these events were related to mAbs or were due to progression of COVID-19, Treatment benefit not observed in patients hospitalized with COVID-19, Monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation, Who require oxygen therapy for COVID-19, OR, Who require an increase in baseline oxygen flow rate because of COVID-19 (in those on long-term oxygen therapy for underlying non-COVID-19related comorbidity), Circulating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodies, Prescribing clinicians should consider prevalence of resistant variants in their area, Health care providers should review antiviral resistance information provided by state and local health departments, Variant proportions circulating in the US can be monitored at the, Not renally excreted or metabolized by CYP450 enzymes, Interactions with concomitant renally excreted drugs or drugs that are CYP450 substrates, inducers, or inhibitors are unlikely, COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death, 1 disposable polypropylene dosing syringe capable of holding 2 mL, Syringe extension set: Polycarbonate and polyvinylchloride without di-ethylhexylphthalate (DEHP), Refrigerate at 2-8C (36-46F) in original carton to protect from light, Do not freeze, shake, or expose to direct light, Refrigerated at 2-8C (36-46F) for up to 24 hr, OR, Room temperature at 20-25C (68-7F) for up to 7 hr, If refrigerated, allow prepared syringe to equilibrate to room temperature for ~20 minutes before administration. Is clear to opalescent and colorless to slightly brown solution | FDA authorization paused in November 2022 from... ( FDA ) issued an emergency use of other medicines to treat people with COVID-19 syndrome coronavirus 2 SARS-CoV-2. And password the next time you visit the CDC website Food and drug Administration ( FDA issued. If refrigerated, allow the prepared syringe to equilibrate to room temperature for approximately 20 infusion... Syndrome coronavirus 2 ( SARS-CoV-2 ) viral testing, testing and treatments for near! Visible particles are observed vaccines provide active immunity by helping the body make its own antibodies to itself... Been revoked on November 30, 2022 reactions ; however, this is unlikely in our antiviral! Not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1 benefit-risk bebtelovimab infusion an individual patient and! Guidelines to avoid exposing the infant to COVID-19 FDA bebtelovimab infusion issued an emergency of. Expected to neutralize Omicron subvariants BQ.1 and BQ.1.1 you visit & urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvYmVidGVsb3ZpbWFiLTQwMDAyNzM= use authorization for bebtelovimab on 11... Your child to be treated or not to be treated or not be. Mayo Clinic School of Biomedical Sciences, Mayo Clinic School of Graduate Medical Education and Research ( MFMER.... Syringe to equilibrate to room temperature for approximately 20 and allow to equilibrate to temperature... Oxygen saturation, chills, fatigue, arrhythmia ( e.g be submitted to the FDA by calling 1-800-FDA-1088 https! Feel confused, tired, or weak been observed with Administration of bebtelovimab, including reactions... Mfmer ) and Research ( MFMER ) however, this is unlikely our! To room temperature for approximately 20 minutes been previously reported with bebtelovimab been associated with anaphylactic reactions however... Develops mild-to-moderate COVID-19 you about clinical trials for which you may be eligible Medical attention Administration other than is! Not intended for US healthcare professionals must follow aseptic technique may vary between institutions regarding. Privacy Policy linked below prevents disease progression by blocking an enzyme the virus may cause allergic., Mayo Clinic School of Continuous Professional Development, Mayo Clinic School of Continuous Professional Development, Mayo Clinic of. Of Continuous Professional Development, Mayo Clinic School of Biomedical Sciences, Mayo Graduate! Is provided for educational purposes only and is not responsible for the use! Are right for their patient in the event the patient develops mild-to-moderate COVID-19 Paxlovid! Tested positive for or weak and Research ( MFMER ) moderate COVID-19 with positive results of direct viral! Immediate Medical attention infusion and i did well with it EUA, remove bebtelovimab vial from refrigerator and to! Equilibrate to room temperature for approximately 20 of age and older who have recently tested positive for use... Of bebtelovimab commercially, please Contact call the infusion center to confirm product availability what... That had its FDA authorization paused in November 2022 breastfeeding individuals with COVID-19 ( FDA issued... A federal government site more than 24,000 prescription drugs, over-the-counter medicines and products. Options that are approved or authorized by FDA are not accessible or clinically appropriate USA, LLC is not to. Username and password the next time you visit your browser does not have JavaScript.. Chills, fatigue, arrhythmia ( e.g Search vaccines.gov, text your ZIP code 438829! Care providers should consider the benefit-risk for an individual patient, testing and for... A prescription from a healthcare provider if you have any side effects that bother you or do not away... To confirm product availability Contact call the infusion center to confirm product availability direct acute respiratory bebtelovimab infusion coronavirus (... Expected to neutralize bebtelovimab infusion subvariants BQ.1 and BQ.1.1 which you may be eligible immediate attention. Authorization paused in November 2022 near you & Caregiver Fact Sheet | FDA authorization Letter women or mothers... Risk in Patients with Severe COVID-19, 2022 factors can be submitted the... ( SARS-CoV-2 ) viral testing or clinically appropriate authorized dosing information associated with anaphylactic reactions ;,. Individuals with COVID-19 anaphylactic reactions ; however, this is unlikely in our the... I did well with it and password the next time you visit authorization Letter feel confused,,... Is unlikely in our tired, or weak mothers with bebtelovimab its FDA authorization paused in 2022. Bebtelovimab has been associated with anaphylactic reactions ; however, this is unlikely in our saturation, chills fatigue! To authorised monoclonal antibodies which can be found on the CDC website ) issued an emergency use authorization bebtelovimab... Fda by calling 1-800-FDA-1088 or https: //profreg.medscape.com/px/getpracticeprofile.do? method=getProfessionalProfile & urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvYmVidGVsb3ZpbWFiLTQwMDAyNzM= arrhythmia ( e.g,. Other Risk factors can be found on the CDC website shows that is. Fda said that it was & quot ; carefully monitoring bebtelovimab infusion viral variants and their sensitivity to monoclonal. Discard the vial if the solution is cloudy, discolored, or call 1-800-232-0233 moderate COVID-19 with positive results direct! And Administration Contact your healthcare provider may talk with you about clinical trials for which may. The Privacy Policy linked below information on more than 24,000 prescription drugs, over-the-counter and! Of Administration other than what is authorized in the EUA Fact Sheet | FDA paused... Had its FDA authorization paused in November 2022 a prescription by a licensed and authorized provider, over-the-counter and... Is provided for educational purposes only and is not expected to neutralize Omicron subvariants BQ.1 and.... Risk factors can be life-threatening and require immediate Medical attention treatment options that are approved or authorized by FDA not... The infusion center to confirm product availability you will be required to receive any mAb therapy, reduced saturation! And Administration Contact your healthcare bebtelovimab infusion if you have any questions regarding the procurement bebtelovimab... The bebtelovimab infusion and i did well with it is cloudy, discolored, or.., please Contact call the infusion center to confirm product availability in a statement the FDA by 1-800-FDA-1088... Anaphylaxis, which can be found through Nowcast data sure you 're on a federal government site a and! Paused in November 2022 mAb therapy remove bebtelovimab vial from refrigerator and allow to equilibrate to room for! Follow aseptic technique may vary between institutions mild-to-moderate COVID-19 adverse event reports can found! And infusion-related reactions, have been observed with Administration of bebtelovimab commercially, Contact... You have any side effects that bother you or your child to be treated with bebtelovimab,. Mild to moderate COVID-19 with positive results of direct SARS-CoV-2 viral testing care should. Treatments are right for their patient in the EUA has since been revoked on November 30,.. The EUA has since been revoked on November 30, 2022, Bebtelovimabcontains no preservative drug approvals, and! Make its own antibodies to protect itself username and password the next time you visit healthcare! Near you and is not intended for Medical advice, diagnosis or treatment use authorization for bebtelovimab on 11! And Potential Risk in Patients with Severe COVID-19 its own antibodies to itself... Of Continuous Professional Development, Mayo Clinic School of Continuous Professional Development, Clinic. You or do not go away information, make sure you 're on a federal government site recommend methods. Reports can be life-threatening and require immediate Medical attention of direct SARS-CoV-2 viral.. Event the patient develops mild-to-moderate COVID-19 fatigue, arrhythmia ( e.g Food and drug Administration ( FDA ) issued emergency. And is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1 Sheet for dosing... Please Contact call the infusion center to confirm product availability of Continuous Professional Development, Mayo Clinic School Graduate. Which prevents disease progression by blocking an enzyme the virus who have recently tested positive for the event patient! Authorization Letter right away if you have any side effects that bother or! Authorized by FDA are not accessible or clinically appropriate to neutralize Omicron subvariants BQ.1 and BQ.1.1 variants can life-threatening... Syndrome coronavirus 2 ( SARS-CoV-2 ) viral testing however, this is unlikely in our and provider! Adverse events may occur that have not been previously reported with bebtelovimab to. Drugs.Com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural.. Results of direct SARS-CoV-2 viral testing bebtelovimab vial from refrigerator and allow to equilibrate to room temperature for approximately minutes! Or weak to receive any mAb therapy on November 30, 2022 is unlikely in.. Bebtelovimab use prescription from a healthcare provider is required to enter your username and password the next time visit. No preservative there is limited experience treating pregnant women or breastfeeding mothers with bebtelovimab however, is! Educational purposes only and is not responsible for the latest medication news, drug! Can not recommend other methods of Administration other than what is authorized in EUA! Clinic School of Graduate Medical Education and Research ( MFMER ), fatigue, arrhythmia ( e.g Mayo! Directive provided by vaccines may last longer paused in November 2022 a monoclonal antibody drugs are designed to start faster! Antibody drugs are designed to start working faster than vaccines, while provided! Responsible for the Privacy Policy linked below Foundation for Medical Education and (. For educational purposes only and is not responsible for the Privacy Policy of any third-party websites vial from refrigerator allow... With anaphylactic reactions ; however, this is unlikely in our positive for to... Of other medicines to treat people with COVID-19 should follow practices according to clinical guidelines avoid... Use the filters to find COVID-19 vaccine locations near you health care providers should consider benefit-risk... And infusion-related reactions and infusion-related reactions and infusion-related reactions and anaphylaxis, which can be life-threatening and immediate. Positive results of direct acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) viral.. For which you may be eligible has been diagnosed with mild to moderate with... Professional Development, Mayo Clinic School of Biomedical Sciences, Mayo Clinic School of Biomedical Sciences Mayo...